Trial Profile

ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Lenalidomide; Rituximab
Indications Follicular lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms HOVON110FL-GLSG-NCRI; ReBeL

Most Recent Events

13 Dec 2022 Status changed from recruiting to discontinued, as per Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
18 Aug 2015 Planned End Date changed from 1 Oct 2025 to 1 Oct 2015, as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com